Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01629082
Recruitment Status : Completed
First Posted : June 27, 2012
Last Update Posted : January 10, 2019
Celgene Corporation
Information provided by:
National Institutes of Health Clinical Center (CC)